Hold Alembic Pharma Ltd For Target Rs.790 - ICICI Direct
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2021/12/481801eba8edbb10f46ee31871a103af.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
US challenges offset domestic performance…
About the stock: Alembic Pharma operates in international generics (US:27% & ExUS:15% in H1FY22), domestic branded (37% in H1FY22) and API (20% in H1FY22).
* Domestic business has 1.5% of market share of IPM with three brands in the top 100. Going ahead, emphasis is on specialty segment with 94% of new launches being specialty products
* The company has invested ~ | 1800 crore in recent years in facilities geared mainly towards US formulations. As of Q2FY22, it has filed 214 ANDA and has 150 approvals with 98 launches in the US
Q2FY22 Results: Alembic reported mixed Q2FY22 results.
* Sales declined 11.3% YoY to | 1292.3 crore
* EBITDA was at | 257.2 crore, down 42% YoY with margins at 19.9%
* Consequent PAT was at | 169.3 crore (down 49.2% YoY)
What should investors do? Alembic’s share price has grown by ~1.4x over the past five years (from ~| 573 in June 2016 to ~| 793 levels in November 2021).
* We maintain our HOLD rating on the stock due to challenging business environment in the US business as well as impending USFDA clearances.
Target Price and Valuation: We value Alembic at | 790 i.e. 20x P/E on FY23E EPS
Key triggers for future price performance:
* Commercialisation of international formulation plants F2 (oncology OSD & injectable), F3 (general injectable & ophthalmic) & F4 (new oral solids)
* Maintains aggressive guidance for capex (| 1000 crore for FY22, FY23) and R&D 12.5-13% of revenues for FY22
* Easing of pricing pressure in US and resolving USFDA issues for timely new launches
* Consistency of performances in Indian branded formulations and diverse portfolio with steady pipeline of speciality medicinesv
Alternate Stock Idea: Apart from Alembic, we like Ajanta Pharma
* Ajanta Pharma is a focused player in branded, which constitutes ~70% of overall sales, which are spread across geographies including India. Focus is on launching maximum number of first time launches with new drug delivery system (NDDS)
* BUY with a target price of | 2500
To Read Complete Report & Disclaimer Click Here
https://secure.icicidirect.com/Content/StaticData/Disclaimer.html
Above views are of the author and not of the website kindly read disclaimer
![](https://portfolio.investmentguruindia.com/uploads/news/insurance 123.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Axis Securities Ltd.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Wipro.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/2b1715f7e03b51b0ac9c014eb224fc1f.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/gdp22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Dollar retures 2.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/health22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Arvind Kapil, MD and CEO, Poonawalla Fincorp.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/stock8.jpg)
Top News
![](https://portfolio.investmentguruindia.com/uploads/news/Monarch networth.jpg)
The USD/INR futures pair has support at 83.10 levels whereas resistance is placed at 83.50 l...
Tag News
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/05/892c2d00d68c33104f9bb896e2cd4a96.jpg)
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
![Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/05/22be0ecb7dfcd46b119b708cd51da380.jpg)
![Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/03/ac1cda4099cf0c445fd6d2081f02ab14.jpg)
![Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/03/6a3f74c50ac1ab127e5882adbac0bbb8.jpg)